Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
AGN 193109 is a potent antagonist of retinoic acid receptors (RARs; Kd = 2, 2, and 3 nM for RARα, β, and γ, respectively).1 It is selective for RARs over retinoid X receptors (RXRs; Kd = >10,000 nM for human RXRα, β, and γ receptors). AGN 193109 reverses changes in cell morphology induced by the RAR agonist TTNPB (Item No. 16144) in ECE16-1 human endometrial ectocervical epithelial cells. It also reverses the growth suppressive effects of all-trans-RA, 13-cis-RA, and 9-cis-RA (Item No. 14587) when used at a 10-fold molar excess. AGN 193109 decreases expression of cytokeratin K5-8, 13, 14, 16, 17, and 19 genes, markers of retinoid action in ECE16-1 cells, when co-administered with TTNPB but not when used alone. In vivo, AGN 193109 induces cleft palate or frontonasal dysplasia and eye malformations in fetuses of pregnant mice following a single oral dose of 1 mg/kg.2
WARNING This product is not for human or veterinary use.
1. AGN193109 is a highly effective antagonist of retinoid action in human ectocervical epithelial cells. The Journal of Biological Chemisty 271(21), 12209-12212 (1996).
2. The use of a retinoid receptor antagonist in a new model to study vitamin A-